001     124357
005     20240228145508.0
024 7 _ |a 10.1161/ATVBAHA.116.308455
|2 doi
024 7 _ |a pmid:28126825
|2 pmid
024 7 _ |a 1079-5642
|2 ISSN
024 7 _ |a 1524-4636
|2 ISSN
024 7 _ |a altmetric:16066548
|2 altmetric
037 _ _ |a DKFZ-2017-01236
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Hasanov, Zulfiyya
|0 P:(DE-He78)133dd4775ba44c855b8725bd4fba11b7
|b 0
|e First author
|u dkfz
245 _ _ |a Endosialin Promotes Atherosclerosis Through Phenotypic Remodeling of Vascular Smooth Muscle Cells.
260 _ _ |a Philadelphia, Pa.
|c 2017
|b Lippincott, Williams & Wilkins
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1524726727_7132
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Vascular smooth muscle cells (VSMC) play a key role in the pathogenesis of atherosclerosis, the globally leading cause of death. The transmembrane orphan receptor endosialin (CD248) has been characterized as an activation marker of cells of the mesenchymal lineage including tumor-associated pericytes, stromal myofibroblasts, and activated VSMC. We, therefore, hypothesized that VSMC-expressed endosialin may display functional involvement in the pathogenesis of atherosclerosis.Expression of endosialin was upregulated during atherosclerosis in apolipoprotein E (ApoE)-null mice and human atherosclerotic samples analyzed by quantitative real-time polymerase chain reaction and immunohistochemistry. Atherosclerosis, assessed by Oil Red O staining of the descending aorta, was significantly reduced in ApoE/endosialin-deficient mice on Western-type diet. Marker analysis of VSMC in lesions induced by shear stress-modifying cast implantation around the right carotid artery identified a more pronounced contractile VSMC phenotype in the absence of endosialin. Moreover, in addition to contributing to neointima formation, endosialin also potentially regulated the proinflammatory phenotype of VSMC as evidenced in surrogate cornea pocket assay experiments in vivo and corresponding flow cytometry and ELISA analyses in vitro.The experiments identify endosialin as a potential regulator of phenotypic remodeling of VSMC contributing to atherosclerosis. The association of endosialin with atherosclerosis and its absent expression in nonatherosclerotic samples warrant further consideration of endosialin as a therapeutic target and biomarker.
536 _ _ |a 321 - Basic Concepts (POF3-321)
|0 G:(DE-HGF)POF3-321
|c POF3-321
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antigens, CD
|2 NLM Chemicals
650 _ 7 |a Antigens, Neoplasm
|2 NLM Chemicals
650 _ 7 |a Apolipoproteins E
|2 NLM Chemicals
650 _ 7 |a CD248 protein, human
|2 NLM Chemicals
650 _ 7 |a Neoplasm Proteins
|2 NLM Chemicals
650 _ 7 |a tumor endothelial marker 1, mouse
|2 NLM Chemicals
700 1 _ |a Ruckdeschel, Tina
|0 P:(DE-He78)506e027e02bbc385e5035a83ed1d8457
|b 1
700 1 _ |a König, Courtney
|0 P:(DE-He78)5ef958977fa3c0658679b496419ce762
|b 2
700 1 _ |a Mogler, Carolin
|0 P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654
|b 3
700 1 _ |a Kapel, Stephanie
|0 P:(DE-He78)8a953c029cb5b686e638301dc826fe59
|b 4
700 1 _ |a Korn, Claudia
|0 P:(DE-He78)9f5445b47d46f5f026560c307119a7da
|b 5
700 1 _ |a Spegg, Carleen
|0 P:(DE-He78)810c43f201aec2aca685353a1b6b5369
|b 6
700 1 _ |a Eichwald, Viktoria
|0 P:(DE-He78)1062e10961e437a74b9dd7542cd4ba7c
|b 7
700 1 _ |a Wieland, Matthias
|0 P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc
|b 8
700 1 _ |a Appak, Sila
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Augustin, Hellmut
|0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
|b 10
|e Last author
773 _ _ |a 10.1161/ATVBAHA.116.308455
|g Vol. 37, no. 3, p. 495 - 505
|0 PERI:(DE-600)1494427-3
|n 3
|p 495 - 505
|t Arteriosclerosis, thrombosis, and vascular biology
|v 37
|y 2017
|x 1524-4636
909 C O |p VDB
|o oai:inrepo02.dkfz.de:124357
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)133dd4775ba44c855b8725bd4fba11b7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)506e027e02bbc385e5035a83ed1d8457
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)5ef958977fa3c0658679b496419ce762
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)8a953c029cb5b686e638301dc826fe59
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)9f5445b47d46f5f026560c307119a7da
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)810c43f201aec2aca685353a1b6b5369
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)1062e10961e437a74b9dd7542cd4ba7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)0792aae05ea250d2937cdfa6c9ca05fc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
913 1 _ |a DE-HGF
|l Herz-Kreislauf-Stoffwechselerkrankungen
|1 G:(DE-HGF)POF3-320
|0 G:(DE-HGF)POF3-321
|2 G:(DE-HGF)POF3-300
|v Basic Concepts
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ARTERIOSCL THROM VAS : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ARTERIOSCL THROM VAS : 2015
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l Vaskuläre Onkologie und Metastasierung
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21